NasdaqGS - Nasdaq Real Time Price USD

Biogen Inc. (BIIB)

Compare
203.30 -1.56 (-0.76%)
At close: August 27 at 4:00 PM EDT
203.90 +0.60 (+0.30%)
Pre-Market: 8:05 AM EDT
Loading Chart for BIIB
DELL
  • Previous Close 204.86
  • Open 204.86
  • Bid 203.17 x 100
  • Ask 203.39 x 100
  • Day's Range 201.88 - 205.00
  • 52 Week Range 189.44 - 270.50
  • Volume 565,193
  • Avg. Volume 1,023,409
  • Market Cap (intraday) 29.613B
  • Beta (5Y Monthly) -0.04
  • PE Ratio (TTM) 25.64
  • EPS (TTM) 7.93
  • Earnings Date Nov 6, 2024 - Nov 11, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 269.61

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

www.biogen.com

7,570

Full Time Employees

December 31

Fiscal Year Ends

Recent News: BIIB

View More

Performance Overview: BIIB

Trailing total returns as of 8/27/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

BIIB
21.44%
S&P 500
17.95%

1-Year Return

BIIB
23.12%
S&P 500
27.69%

3-Year Return

BIIB
40.60%
S&P 500
25.86%

5-Year Return

BIIB
9.14%
S&P 500
95.45%

Compare To: BIIB

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: BIIB

View More

Valuation Measures

Annual
As of 8/27/2024
  • Market Cap

    29.61B

  • Enterprise Value

    34.36B

  • Trailing P/E

    25.64

  • Forward P/E

    14.18

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    3.07

  • Price/Book (mrq)

    1.86

  • Enterprise Value/Revenue

    3.55

  • Enterprise Value/EBITDA

    15.97

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    11.98%

  • Return on Assets (ttm)

    5.19%

  • Return on Equity (ttm)

    7.63%

  • Revenue (ttm)

    9.67B

  • Net Income Avi to Common (ttm)

    1.16B

  • Diluted EPS (ttm)

    7.93

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.91B

  • Total Debt/Equity (mrq)

    41.91%

  • Levered Free Cash Flow (ttm)

    1.27B

Research Analysis: BIIB

View More

Company Insights: BIIB

Research Reports: BIIB

View More

People Also Watch